As the CGT industry continues to demonstrate huge potential for the treatment of disease, including cancer, scalable and cost-effective CGT manufacturing has become essential.
According to ScaleReady, simplicity and repeatability are the key to practical scale out of CGT manufacturing and the integration of Cellular Origins’ robotic system will advance that objective.
One area for improvement is the industry’s reliance on labour to facilitate sterile interconnections, which creates complexities and introduces risk of error.
The first project under the new collaboration will be to standardise and automate interconnections between the modules of ScaleReady’s G-Rex manufacturing platform, used by therapy developers to produce CGTs for clinical trials.
This integration of Cellular Origins’ robotic system will eliminate variability in manual connection techniques.
Further projects will automate additional components of ScaleReady’s workflow, such as the robotic movement of G-Rex into and out of incubators.
“ScaleReady’s technologies are widely adopted in the production of advanced, cell-based therapies,” said Dr Edwin Stone, CEO of Cellular Origins.
“This collaboration demonstrates the adaptability of our robotic system, highlighting that it can be integrated seamlessly into existing workflows and allowing therapy developers access to scalable, cost-effective advanced therapy manufacture without significant process redevelopment.”
Josh Ludwig, commercial director at ScaleReady, said he plans to utilise the partnership to create a “viable pathway using cell therapies for larger patient indications and front-line treatments by enabling therapy developers to implement automation.”
